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Cotrimoxazole-induced SIADH — a unique challenge during 
treatment of pulmonary nocardiosis
Abstract
A 62 year old male non-smoker diagnosed with pulmonary nocardiosis was initiated on Cotrimoxazole therapy at a dose of 20 
mg/kg per day in three divided doses. He developed hyponatremia (serum sodium 105 mEq/L) on day 3 of therapy. The potential 
causes of hyponatremia were evaluated. After ruling out other causes, the cause was suspected to be Cotrimoxazole-induced 
syndrome of inappropriate anti-diuretic hormone secretion (SIADH). We subsequently re-initiated therapy with Cotrimoxazole and 
the hyponatremia (serum sodium 110 mEq/L) recurred. Upon discontinuation of therapy, serum sodium levels returned to normal. 
The patient was started on Amoxycillin-Clavulanic Acid as an alternative therapy for pulmonary nocardiosis which resulted in 
resolution of the hyponatremia. Cotrimoxazole-induced SIADH is a rare occurrence. This case is representative of a patient with 
Cotrimoxazole-induced SIADH and the causal relationship was confirmed once resumption of therapy with the offending medi-
cation resulted in hyponatremia. 
Clinicians should be aware of this rare adverse effect of Cotrimoxazole and should monitor serum electrolytes during therapy, 
especially in the elderly and in those receiving high doses.
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Introduction
Pulmonary nocardiosis, previously thought 
of as a disease that occurs mainly in the immu-
nocompromised population, has become increas-
ingly reported in individuals with structural 
lung diseases [1, 2]. Cotrimoxazole is the drug of 
choice for the treatment of nocardiosis. Although 
widely considered to be a drug with a decent 
safety profile, it has its own major and minor 
adverse effects [3, 4]. SIADH is a rare but serious 
complication associated with Cotrimoxazole ther-
apy. Its occurrence is more frequently observed 
than previously recorded. SIADH is a disorder 
caused by the inability to suppress secretion of 
anti-diuretic hormone. There is impairment of 
water excretion and if water intake is in excess 
of urine output, water retention occurs leading to 
hyponatremia [5, 6]. The risk appears to be high-
est in the elderly population and is essentially 
dose-dependent [5, 7].
Case history
A 62-year-old male non-smoker was admitted 
due to complaints of acute worsening of breathless-
ness, fever, and cough with expectoration that had 
been present for 5 days. The fever was intermittent 
and high grade, and was associated with chills and 
rigor. Cough was productive with copious yellow-
ish non-foul-smelling sputum. He had a history of 
sputum smear-positive pulmonary tuberculosis 
six years ago for which he received antitubercular 
therapy. He had developed obstructive airway dis-
ease as a sequela of pulmonary tuberculosis which 
was confirmed by spirometry. He was treated with 
inhaled bronchodilators for five years.
On admission he was severely ill, febrile (oral 
temperature 38.9°C), tachypneic, tachycardic, 
and normotensive with an oxygen saturation of 
82% on room air. 
Respiratory system examination revealed 
bilateral diffuse coarse crackles and rhonchi. 
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Other systemic examinations were unremarkable.
On evaluation, he had neutrophilic leuko-
cytosis. The total count was 21,010 (89% neu-
trophils). Liver and renal function parameters 
were normal. Other unordinary lab results were 
documented as follows: serum sodium on ad-
mission was 134 mg/dL, the C-reactive protein 
level was 190 mg/L, and serum procalcitonin 
was 2.86 ng/mL. Chest X-ray showed bilateral 
non-homogenous opacities with haziness over 
the right upper zone (Figure 1).
He was started on empirical antibiotic ther-
apy with IV Piperacillin-Tazobactam (4.5 g 4 ×/ 
/diem) and oral Azithromycin (500mg 1 ×/diem). 
Oxygen supplementation, nebulized bronchodila-
tors, and other supportive therapy was provided. 
On day four, in view of inadequate clinical im-
provement, a contrast-enhanced computed tomo-
gram of the thorax was completed which showed 
ground-glass opacities over the right upper lobe 
with multiple bilateral patchy areas of consolida-
tion and centrilobular nodules (Figure 2).
Flexible fiberoptic bronchoscopy was planned 
and completed under continuous oxygen supple-
mentation by nasal cannula with a target oxygen 
saturation of 90%. It showed purulent secretions 
from the right lobar and segmental bronchi. Bron-
chial anatomy was normal and aerobic cultures 
of bronchial secretions, Ziehl Nielsen staining, 
Gram-staining, Mycobacterium culture were sent. 
There was no bronchoscopy-related complication. 
An aerobic culture of bronchial fluids showed 
growth of Nocardia (the specific species were 
not identified). Modified acid-fast bacilli (AFB) 
stain after bronchial lavage showed filamentous 
branched acid-fast positive bacilli. Fungal stain 
and culture were negative. Mycobacterium cul-
ture was negative at the end of the required 42-day 
culture period.
As part of the Nocardia pneumonia treat-
ment regimen, the patient was started on oral 
Cotrimoxazole at a dose of 20 mg/kg body weight. 
After 3 days of treatment, the patient developed 
asymptomatic hyponatremia. Sodium levels had 
fallen from 134 mEq/L to 129 mEq/L, and then 
subsequently to 105mEq/L. Even at this point, 
he did not have any symptoms. Causes of this 
electrolyte imbalance were investigated. Thy-
roid function tests were done and serum cortisol 
was measured and both results were found to 
be normal. A CT scan of the brain was normal. 
After ruling out other causes, the cause of the 
hyponatremia was suspected to be Cotrimoxaz-
ole-induced SIADH (serum sodium 105 mEq/L, 
urine osmolality 468 mOsm/kg, serum osmolality 
250 mOsm/kg, and urine sodium 82 mmol/L). Flu-
id restriction was initiated, and hypertonic saline 
was administered. Cotrimoxazole was stopped 
and serum sodium levels returned to normal after 
continuing the above measures.
Since the treatment of Nocardia involves 
the use of long-term antibiotics, we decided to 
re-introduce Cotrimoxazole to see if it was the 
cause of the hyponatremia. On reintroduction 
of Cotrimoxazole, a fall in serum sodium levels 
was observed by day 3 (a level of 110 mEq/L). As 
a result, Cotrimoxazole was stopped and the pa-
tient was started on IV Amoxycillin-clavulanate 
(1.2 g, 3 ×/diem) as an alternative regimen. He 
received parenteral antibiotics for 10 days. There 
was a serial fall in total WBC count to 14,320, and 
serum procalcitonin had fallen from an initial 
2.86 ng/mL to 0.11 ng/mL. The patient’s clinical 
condition improved gradually and he was weaned 
off oxygen therapy while continuing therapy 
with Amoxycillin-clavulanate (625 mg 3×/diem) 
which was now administered orally. He was 
discharged in a stable condition and advised to 
continue oral Amoxycillin-clavulanate therapy at 
a dose 625 mg thrice daily for a duration of three 
months. Subsequent chest radiographs taken on 
follow up after 40 days of therapy showed signifi-
cant clearance of radiological opacities (Figure 3). 
Figure 1. Chest radiograph PA view showing multiple bilateral air 
space opacities and bilateral flattened diaphragms
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Discussion
Nocardiosis is classically known to be an 
opportunistic infection associated with impaired 
immunity, particularly cell-mediated immunity. 
However, up to one-third of patients have been 
found to be immunocompetent [2, 8]. 
Risk factors for Nocardiosis include infec-
tion with the Human Immunodeficiency Virus, 
transplants, cancers, rheumatic diseases, diabe-
tes mellitus, steroid abuse, chronic obstructive 
pulmonary disease, and poor socio-economic 
conditions [8, 9].
Pulmonary involvement is the most common 
presentation of nocardiosis. Symptom onset 
may be acute, sub-acute or chronic and includes 
cough, dyspnea, chest pain, hemoptysis, fever, 
weight loss, and fatigue [2, 10]. Lobar consolida-
tion is the most common radiographic presenta-
tion, followed by nodules/reticulations [10].
Although Trimethoprim-Sulfamethoxazole is 
the mainstay of treatment, the final drug regimen 
is decided on the basis of antimicrobial sensitiv-
ity, the severity of the disease process, and the 
organ of involvement [2, 10]. 
Cotrimoxazole is a sulfonamide antibiotic 
which contains Trimethoprim and Sulfamethox-
azole. Trimethoprim is a heterocyclic weak base 
and is related in structure to the potassium-spar-
ing diuretics amiloride and triamterene which 
act by blocking sodium reabsorption at the eNaC 
(epithelial sodium channel) in the distal nephron 
[10]. High doses of TMP has been shown to act 
as epithelial sodium channel inhibitors in the 
distal tubule.
SIADH can be caused by a variety of pul-
monary and extra-pulmonary infections/malig-
nancies, as well as by a range of medications [7]. 
SIADH is a common cause of hyponatremia. In 
a retrospective cohort study by Tsapepas et al, the 
incidence of hyponatremia was found to be 72.3% 
among those on high dose therapy with Cotrimox-
azole [4]. Severe hyponatremia and SIADH is rare 
and described in only a few case-reports [11, 12].
In describing hyponatremia and its treatment, 
the cerebral effects are worth mentioning. The rate 
of sodium correction in hyponatremia of acute 
onset should be < 10mEq/L in the first 24 hours 
and < 8mEq/L for any 24-hour period thereafter. 
Effective serum osmolality is determined by serum 
sodium concentration. Hypotonic hyponatremia, 
if acute and severe, can lead to the entry of wa-
ter into brain cells and ultimately, to cerebral 
edema [13, 14]. The brain adapts to such a level 
of hypotonicity by losing intracellular solutes, 
principally potassium and organic solutes called 
osmolytes. Hyponatremia, which develops within 
two or three days, is less likely to be complicated 
by cerebral edema because of this brain adapta-
tion. Once the adaptation is complete, the rate of 
correction of hyponatremia is important. Overt 
rapid correction of hyponatremia can induce 
Osmotic Demyelination Syndrome (ODS) [13]. 
However, rapid correction in acute and severe 
hyponatremia does not induce ODS because the 
cerebral adaptation is still in its early stage [14].
In our case, the patient’s thyroid and adrenal 
function, as well as brain imaging, were normal. 
Figure 2. Contrast-enhanced tomogram of the thorax showing bilateral 
upper lobe ground-glass opacities and right upper lobe consolidation
Figure 3. Chest radiograph showing clearance of previously noted 
opacities during follow-up
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In view of no other plausible explanation for the 
hyponatremia, we considered Cotrimoxazole as 
the likely causative agent. The presence of low 
serum osmolality, high urine osmolality, and high 
urinary sodium in the absence of hypothyroidism 
and peripheral signs of hypovolemia pointed 
towards a potential iatrogenic cause. Once the 
hyponatremia was resolved with the cessation 
of Cotrimoxazole, and subsequently reappeared 
when therapy was re-started, the diagnosis of 
Cotrimoxazole induced-SIADH was evident.
Conclusion
This case report presents a rare but poten-
tially fatal complication associated with Cotri-
moxazole therapy: SIADH. Probable risk factors 
for this in our case are advanced age and a high 
dose of Cotrimoxazole. A high index of suspicion 
and close monitoring of serum electrolytes is 
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